Eli Lilly & Co. (LLY)’s injectable form of the antipsychotic Zyprexa is being investigated by U.S. regulators after two patients died three to four days after receiving the drug.
The two patients, given intramuscular injections of Zyprexa Relprevv, were later found to have very high levels of the drug in their systems, which can cause delirium, cardiac arrest and arrhythmias and coma or loss of consciousness, the Food and Drug Administration said in a statement today. The agency isn’t calling the deaths an overdose, and said the patients hadn’t been given an inappropriate amount of the drug.
